Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation.

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is ...

James Chen, CMT is an expert trader, investment adviser, and global market strategist. Charlene Rhinehart is a CPA , CFE, chair of an Illinois CPA Society committee, and has a degree in accounting and ...

Terra Innovatum Global faces significant regulatory, cost, and execution risks, with FOAK commercialization by 2027 highly ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...

Behind the US regime change operation aginst Venezuela is the unique, strategic role, Venezuela plays in the global economy – ...

Editorial Note: We earn a commission from partner links on Forbes Advisor. Commissions do not affect our editors' opinions or evaluations. Disclaimer: Calculator results and default inputs are ...

Applied Digital’s latest narrative update leaves its fair value estimate unchanged at $43.70 per share, even as a slightly higher discount rate edges up the perceived risk tied to its long dated AI ...

Wondering if Tilray Brands is finally priced for a turnaround or still just a speculative cannabis play? Let us unpack what the current share price is really implying about its future. Tilray’s stock ...

Factor meals provides fully prepared meals designed by registered dietitians. Meal delivery is a convenient meal solution for busy individuals looking to maintain a balanced diet. Our testers tried ...

Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...